Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04035850
Other study ID # 7206
Secondary ID
Status Withdrawn
Phase Phase 3
First received
Last updated
Start date August 1, 2019
Est. completion date August 1, 2021

Study information

Verified date January 2024
Source St. Joseph's Healthcare Hamilton
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The present study is a single-group open-label investigation of the potential efficacy of Vortioxetine for treatment of 30 adult volunteers with Hoarding Disorder (HD) (flexible-dose study, with a target dose range 5-25mg). The proposed study will be the first Vortioxetine study in HD, and conducted at the Anxiety Treatment and Research Clinic (ATRC) Canada's largest academic anxiety clinic, a regional referral center for individuals with HD. The study requires a Letter of No Objection from Health Canada and the study will be approved by Hamilton Integrated Research Ethics Board (HiREB).


Description:

Hoarding disorder (HD) is a common and severe new diagnostic category. HD has two core dimensions: difficulty discarding items and the resultant clutter, which may preclude the use of living spaces for their intended. Other HD criteria, distress and impairment, often include unemployment, removal of children, health risks (e.g. infestations, falls, fires, etc.). The estimated prevalence of hoarding is 5.3% in adults and 2% in youth. Existing treatments of hoarding are only partially effective. Emerging evidence supports the partial efficacy of cognitive behavioral therapy (CBT) in the treatment of HD though, paradoxically, this therapy mostly addresses the excessive attachment to possessions but not the above-identified cognitive deficits. On the other hand, the study of pharmacological treatments for hoarding is in preliminary stages and there currently are no well-validated or official guidelines for the use of psychotropic medications in HD. Given that HD is a highly prevalent and severe condition, there is an urgent need to address this gap in the literature to improve the well-being of patients with the disorder. Emerging evidence suggests that serotonergic medications may have an important role in the treatment of HD. First, HD is highly comorbid with obsessive-compulsive disorder (OCD) and major depressive disorder (MDD), two disorders that respond well to serotonergic medications. Second, a recent meta analysis of 14 clinical trials suggested that hoarding symptoms had responded to selective serotonin reuptake inhibitor (SSRIs) (i.e., paroxetine and sertraline) and venlafaxine, a serotonin and norepinephrine reuptake inhibitor, with response rates ranging between 37%-76% of participants. Interestingly, this response rate is similar to response rates reported by meta-analyses of the treatment response of OCD to SRIs. However, those findings should be interpreted with caution given the lack of controlled studies and the diagnostic heterogeneity, the latter a result of the diagnostic ambiguity that prevailed prior to the introduction of HD in the fifth version of the Diagnostic and Statistical Manual (DSM-5). Treatment of hoarding symptoms should ideally target the obsessional aspect of the syndrome (abnormal attachment to possessions), some or all of the identified cognitive deficits and commonly associated comorbidities. Although preoccupation with possessions, an OCD/MDD-like feature of hoarding, can arguably be addressed by the use of Serotonin reuptake inhibitors (SR) medications that are highly effective for the treatment of OCD and MDD , targeting cognitive deficits in hoarding likely requires a different approach and the use of newer generation serotonergic medications. Vortioxetine is a novel serotonergic antidepressant with a unique pharmacodynamics profile, reported precognitive effects and proven efficacy for the treatment of MDD . Vortioxetine is a 5-HT3, 5-HT7 and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and serotonin (5-HT) transporter (SERT) inhibitor. There is preliminary evidence that Vortioxetine's unique serotonergic modulation profile may be associated with distinct mechanisms of action at the brain network level. In addition, several studies1 report that Vortioxetine is associated with improved cognitive performance in patients with MDD. These procognitve effects appear to distinguish Vortioxetine from other antidepressant agents. As such, Vortioxetine should be considered a prime candidate for medication trials in HD. To date, however, no studies of vortioxetine in HD have been published. With this in mind the goal of the present study is to conduct a preliminary, single-group open-label investigation of the potential efficacy of Vortioxetine for treatment of 30 adult volunteers with HD (flexible-dose study, with a target dose range 5-25mg). The proposed study will be the first Vortioxetine study in HD, and conducted at the ATRC Canada's largest academic anxiety clinic, a regional referral center for individuals with HD. The study requires a letter of no objection from Health Canada and the study will be approved by Hamilton Integrated Research Ethics Board (HiREB).


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date August 1, 2021
Est. primary completion date August 1, 2021
Accepts healthy volunteers No
Gender All
Age group 25 Years to 65 Years
Eligibility Inclusion Criteria: 1. a principal DSM-5 diagnosis of HD 2. SI-R score>=40 3. age between 25-65 4. no other antidepressant use in the 4 weeks that precede the first Vortioxetine dose* 5. ability to provide written informed consent - Patients on non-Vortioxetine antidepressant who are willing to participate in the study and meet all other inclusion and exclusion criteria will be offered a 4-week antidepressant wash out period. Exclusion Criteria: 1. current or past diagnosis of mania/hypo-mania, psychotic disorder or a 1st-degree relative with bipolar disorder or a psychotic disorder 2. past history of behavioural activation or suicidal ideations on antidepressant medication 3. known hypersensitivity to Vortioxetine 4. concomitant use of other antidepressants 5. current participation in CBT for HD or OCD 6. concomitant use of a MAO inhibitor 7. known hepatic insufficiency 8. pregnancy.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Vortioxetine Tablets
Strength 5-20 mg

Locations

Country Name City State
Canada St Joseph Healthcare Hamilton Ontario

Sponsors (1)

Lead Sponsor Collaborator
Noam Soreni

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Saving-inventory Revised (SI-R) A self report scale.23-item self-report measure comprising three subscales: difficulty discarding, clutter, and excessive acquisition .
Items on the SI-R are scored between 0 and 4, with higher scores indicating greater hoarding severity. Total score = sum of all items Range = 0-92. A total score of >46 represents clinically significant hoarding
12 weeks
Primary Hoarding cognitions Inventory Saving cognition Inventory A self report scale that measures hoarding related cognitions.24-item self-report measure of hoarding severity.
Items on the SI-R are scored between 1 and 7, with higher scores representing more severe hoarding symptoms. indicating Total score = sum of all items, Range = 0-168. Mean score in non clinical population - 42, SD-20; mean score in individuals with HD 95.9 , SD=31.0.
12 weeks
Secondary Activities of daily life of hoarding (ADL-H) A self report scale to assess hoarding-related functional impairment
Total score = sum all 15 items after excluding those rated "Not Applicable"; divide the summed score by the number of items given a numerical rating. This will yield an average of all applicable items. Range = 1-5, score greater than 3 suggests marked functional impairment.
12 weeks
Secondary Cognitive changes 1 Cambridge cognition tests:
Cambridge Gambling Task Multitasking Test Spatial span test Stockings of Cambridge Stop Signal Task
12 weeks
Secondary Cognitive changes 2 Digit Symbol Substitution Test (DSST) 12 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02843308 - Enhancing Treatment of Hoarding Disorder With Personalized In-Home Sorting and Decluttering Practice N/A
Active, not recruiting NCT02306174 - Cognitive Rehabilitation and Exposure-based Class for Compulsive Hoarding N/A
Not yet recruiting NCT04811807 - Clinical Response of Impulsivity After Brain Stimulation in Parkinson's Disease
Completed NCT02584764 - Internet Supported Group Cognitive Behavior Therapy (CBT) for Hoarding Disorder (HD) N/A
Completed NCT04270825 - Group Treatment for Hoarding Disorder N/A
Active, not recruiting NCT02402647 - Cognitive Rehab and Exposure Treatment for Hoarding N/A
Enrolling by invitation NCT05254015 - Cognitive Rehabilitation and Exposure Therapy for Geriatric Hoarding N/A
Recruiting NCT05237466 - Motivational Interviewing to Enhance Behavioral Change in Older Adults With Hoarding Disorder N/A
Recruiting NCT04697849 - Functional and Cognitive Rehabilitation of Hoarding Disorder N/A
Active, not recruiting NCT03487224 - Neural Mechanisms of Decision Making in Hoarding Disorder
Completed NCT01451697 - Cognitive Remediation for Neuropsychological Impairment in Compulsive Hoarding Early Phase 1
Completed NCT03828461 - Hoarding Disorder Treatment With Virtual Reality N/A
Recruiting NCT04712474 - In-home Decluttering Augmentation of Group CBT for HD N/A
Completed NCT02367430 - Critical Time Intervention for Individuals With Hoarding Disorder N/A
Active, not recruiting NCT03734705 - Imaginal Exposure for Hoarding Disorder N/A
Not yet recruiting NCT03772301 - Evaluation of Hoarding Behaviour and Eating Disorders Among Holocaust Survivors and Their Descendants
Completed NCT02377986 - Augmenting Buried in Treasures Workshop (BIT) With In-home Decluttering Practice for Individuals With Hoarding Disorder N/A
Completed NCT02040805 - Comparison of Treatment for Hoarding Disorder N/A
Completed NCT04239729 - Web-based Acceptance and Commitment Therapy for Hoarding Disorder N/A
Recruiting NCT05985356 - Neuromodulation for Comorbid Hoarding Disorder and Depression N/A